Valeant Pharmaceuticals’ (NYSE:VRX) second-quarter earnings report didn’t include any surprises, and despite lackluster results, the company’s plan to get back on firm financial ground helped shares soar earlier today. Can Valeant Pharmaceuticals overcome its challenges and get back to growth? Here’s how CEO Joseph Papa plans to do it.

Read the full article at